Join us again at the only FREE TO ATTEND (for drug developers & academics) industry-dedicated summit focused on advancing the best-in-class kinase inhibitor products with enhanced specificity, ...

Australia's CSL has said its one-monthly treatment for hereditary angioedema has shown it is safe and effective in a phase 3 trial, and will be filed for approval in its current financial year which ...